Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Feds move to streamline oversight of gene therapy

Collins FS and Gottlieb S. N Engl J Med. doi: 10.1056/NEJMp1810628

Publish date:: September 13, 2018

Key clinical point: NIH and FDA are looking to streamline gene therapy development oversight.

Major finding: The proposal would return the function of the Recombinant DNA Advisory Committee (RAC) to a function more in line with its original mission.

Study details: Full proposal details are to be published in the Federal Register on Aug. 17.

Disclosures: The agency leaders reported no relevant disclosures in the production of the proposal.

Read the article.

Citation:

Collins FS and Gottlieb S. N Engl J Med. doi : 10.1056/NEJMp1810628

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gene Therapy

Gene therapy effective in hemophilia B patients with neutralizing antibodies,

BCL11A-directed gene therapy advances in sickle cell disease,

SB-525 Gene Therapy Promising for Hemophilia A,

Padua variant factor IX gene shines in AMT-061,

Gene therapy reverses sickle cell phenotype in small study, Esrick EB et al. ASH 2018, Abstract 1023